Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies

Table 1

Summary of clinical trials comparing lipid effects of pioglitazone and rosiglitazone.

	Concomitant glucose/lipid therapy	𝑁	Duration	Pioglitazone effects	Rosiglitazone effects
Derosa et al. [16, 17]	Glimepiride	91	52 wk	↑HDL-C, apo AI ↓TC^*, LDL-C^*, ↓TG^*, apo B^*, Lp(a)^*	↑TC^*, LDL-C^*, HDL-C, ↑TG^*, apo AI, apo B^*, lipoprotein (a)
Goldberg et al. [10], Deeg et al. [11]	None	802	24 wk	↑HDL-C^*, LDL-C^*, TC^*↓TG^*↑VLDL-P, HDL-P^*, apo AI ↓LDL-P^*, apo CIII^*	↑TG^*, HDL-C^*, LDL-C^*, ↑TC^*, apo B^*↑VLDL-P, HDL-P^*, LDL-P^*, apo CIII^*↓apo AI^*
Berhanu et al. [19]	Statins	305	17 wk	↓TG^*, TC^*, LDL-P, ↑LDL-C^*, HDL-C (changes following switch from rosiglitazone to pioglitazone)
Chappuis et al. [15]	None	17	12 wk	↓AUC-TG^*↑CETP^*	↑AUC-TG^*↓CETP^*
Derosa et al. [18]	Metformin	96	52 wk	↓TC^*, LDL-C^*, TG^*, apo B^*↑HDL-C^*, apo AI^*	No significant changes in any lipid parameter
Berneis et al. [14]	None	9	12 wk	↑TC, HDL, LDL, LDL IIA^*↓TG^*	↑TC, TG^*, HDL, LDL, LDL-IIA

𝑁 = number of patients enrolled. Pioglitazone and rosiglitazone effects are summarized as % change from baseline and listed in parentheses. (^*) indicates a statistically significant change from baseline. TC = total cholesterol, TG = triglycerides, LDL-C = LDL cholesterol, HDL-C = HDL cholesterol, LDL-P = LDL particle number, HDL-P = HDL particle number, apo = apolipoprotein, AUC-TG = area under the curve for TG.